Research output per year
Research output per year
Personal profile
Biography
I am Professor of Medicines Discovery at the Institute of Neuroscience and Cardiovascular Research. I have >25 years' experience in drug discovery and clinical development in academia and industry, working on a range of therapeutic targets and indications. I have deep expertise in enzymology and small molecule R&D across neurodegenerative, metabolic, and inflammatory diseases.
I was co-founder and CSO/CTO of Kynos Therapeutics from inception through financing to acquisition by Dr. Falk Pharma GmbH. I am inventor of emestedastat/Xanamem, licensed to Actinogen Medical and in late-stage clinical development in patients with Alzheimer’s disease.
My research in a nutshell
The primary focus of my research is drug discovery. I conduct translational research with a focus on discovering and developing small molecules as medicines for the treatment of various unmet needs. This is research is highly collaborative with close involvement of both academic and industry collaborators across a range of discplines. My research has led to the discovery of a number of potent small molecule inhibitors of target enzymes, which have been out-licensed and are progressing through clinical trials in humans. I provide expertise in target validation through assay development and in vitro screening to lead optimisation and clinical candidate selection.
Education/Academic qualification
Doctor of Philosophy (PhD), A system for the generation and identification of mutant DNA-binding proteins, University of Edinburgh
Award Date: 1 Jan 1995
Bachelor of Science, University of Edinburgh
Award Date: 1 Jan 1991
Fingerprint
Dive into the research topics where Scott Webster is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Pharmacological inhibition of hydroxysteroid 11-beta dehydrogenase type 1 (11-βHSD1) after myocardial infarction preserves cardiac function in a translational mini-pig model
Al Disi, S., Ascione, R., Khan, S., Johnson, T., Sammut, E., Bruno, V. D., Baz Lopez, D., James, C.-A., Simpson, J., Homer, N. Z., Millar, M., Singh, T., von Kreigsheim, A., Mills, N. L., Walker, B. R., Andrew, R., Webster, S. P., Whittaker, A., Freeman, A. & Gray, G. A., 28 Dec 2025, (E-pub ahead of print) In: British Journal of Pharmacology.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Small Interfering RNA Therapy Targeting the Long Noncoding RNA SMILR for Therapeutic Intervention in Coronary Artery Bypass Graft Failure
Brown, S. D., Malinowska, A. L., Bennett, M., Correa-Sánchez, A. F., Horcasitas Valencia, L. L., Lucignoli, A. P., Barton, A. K., Clark, L., Sluimer, J. C., Webster, S. P., Rodor, J., Newby, D. E., Cunningham, M. & Baker, A. H., 1 Nov 2025, In: JACC: Basic to Translational Science. 10, 11, 25 p., 101364.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Discovery and exploration of disubstituted [1,2,5]oxadiazolo-[3,4-b]pyrazines as novel C-C chemokine receptor type 5 signaling inhibitors targeting the intracellular allosteric binding pocket
Billen, M., Reynders, S., Claes, S., Kleinboelting, S., Rozenski, J., Bulai, R.-G., Rocca, E., Homer, N. Z. M., Webster, S. P., Kaminski, T. P., Lescrinier, E., Schols, D. & Verwilst, P., 5 Jul 2025, In: European Journal of Medicinal Chemistry. 291, 117600.Research output: Contribution to journal › Article › peer-review
-
Optimization of Cyclophilin B-Targeted Tri-vector Inhibitors for Novel MASH Treatments
Kouridaki, M.-E., Gillespie, J., Robinson, J., Mathie, T., Bain, L., Mcarthur, D., Morrison, A., Greenslade, D. B., Papadourakis, M., Maj, K., Cameron, K., Turner, D., Webster, S. P., Wear, M. A., Doughty-Shenton, D., Hulme, A. N. & Michel, J., 12 Mar 2025, (E-pub ahead of print) In: Journal of Medicinal Chemistry.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Kynurenine monooxygenase blockade reduces endometriosis-like lesions, improves visceral hyperalgesia, and rescues mice from a negative behavioural phenotype in experimental endometriosis.
Higgins, B., Simitsidellis, I., Zheng, X., Collins, F., Homer, N. Z. M., Denham, S. G., Simpson, J. P., Millar, M., Boswell, L., Lee, H. Y., Kim, Y. G., Park, K. H., Park, L. C., Sweeney, P. J., Feraille, G., Taddei, A., Chagras, D., Alvaraz, T., Webster, S. P. & Horne, A. & 2 others, , 2 Aug 2024, In: eLIFE.Research output: Contribution to journal › Article › peer-review
Open AccessFile
Projects
- 21 Finished
-
Personalized Treatment For Pleural Mesothelioma Patients By Taming The Hippo
Hansen, C. (Principal Investigator), Carragher, N. (Co-investigator), Carragher, N. (Co-investigator) & Webster, S. (Co-investigator)
1/12/21 → 31/10/23
Project: Research
-
Targeting the long non-coding RNA SMILR using small interfering RNA for therapeutic intervention in vein graft failure
Baker, A. (Principal Investigator), Mahmoud, A. (Co-investigator) & Webster, S. (Co-investigator)
1/05/21 → 30/06/23
Project: Research
-
Generating small molecule inhibitors of ENPP1 for cancer treatment
Webster, S. (Principal Investigator)
1/02/21 → 30/06/22
Project: Research
-
Targeting S100A8/A9 as a new anti-inflammatory treatment for Cystic Fibrosis
Webster, S. (Principal Investigator)
1/09/20 → 23/11/21
Project: Research
-
Targeting S100A8/A9 as a new anti-inflammatory treatment for Cystic Fibrosis
Hay, D. (Principal Investigator), Gray, R. (Co-investigator) & Webster, S. (Co-investigator)
1/09/20 → 23/11/21
Project: Research
Press/Media
-
BioQuarter signs deal with pharmaceutical giant GSK to tackle pancreatitis
23/10/11
12 items of Media coverage
Press/Media: Research